News Headlines Trigger Momentum For These Penny Stocks
Are penny stocks on your watch list right now? If not, you may want to think about it a bit more because they’ve become some of the market’s most popular assets. Additionally, they’re becoming some of the most heavily traded stocks to watch, in general.
While there are plenty of these companies listed on the OTC Exchange, major exchanges like the NYSE and Nasdaq are experiencing a surge of interest in these cheap stocks. Despite Thursday’s sell-off, some of the most active stocks in the market were trading under $5.
To put it into perspective, out of the top 50 highest volume stocks in the market, over 20% were penny stocks. This trend isn’t new either. If you recall, when markets were trending higher, a vast majority of the highest volume stocks were those under $5 per share.
One of the biggest drivers of this trend is market volatility. When markets move higher, traders look for stocks that experience big swings to capitalize on short-term breakouts. Who knew a longer-term uptrend would be “boring”? On the other hand, when markets slip, traders have sought out penny stocks as somewhat of a respite from the bearish selling. In any case, with markets trading higher on Friday morning, the sentiment is bullish.
Penny Stocks To Watch With News
With this as the backdrop on Friday, there is already a slew of penny stocks to watch. Here are 5 that have just released big news and are also on the move, early in the morning session.
- Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)
- Purple Biotech Ltd. (NASDAQ: PPBT)
- SenesTech Inc. (NASDAQ: SNES)
- Check-Cap Ltd. (NASDAQ: CHEK)
Tonix Pharmaceuticals
This clinical-stage biotech company develops treatments for central nervous system and immunology diseases. Something that has placed Tonix in focus is its progress in developing a COVID-19 vaccine candidate. The company’s TNX-1800 is it being studied in animals right now and efficacy data has already shown promise. But on Friday, attention is on another one of the company’s treatments.
Penny Stocks News You Can Use
Its TNX-601 CR is being designed for once-daily treatment for major depressive disorder, PTSD, and neurocognitive dysfunction. This week, the company revealed that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,946,027 to the company on March 16, 2021. The new patent is titled “Tianeptine Oxalate Salts and Polymorphs.” It includes claims directed to pharmaceutical compositions “comprising crystalline tianeptine oxalate salts and methods of using those compositions to treat various disorders and to methods of producing the oxalate salts. “
Read More
- 4 High Volume Penny Stocks To Watch This Week
- Making A List Of Penny Stocks Right Now? 3 Names To Know For March
Tianeptine oxalate is the active ingredient in TNX-601 CR. This patent is expected to provide Tonix with U.S. market exclusivity until December 28, 2037, excluding any patent term extensions.
Purple Biotech Ltd.
Another one of the biotech penny stocks hitting watch lists after the news today is Purple Biotech. The company is developing cancer treatments. The company’s oncology pipeline includes NT219 and CM24. NT219 is being designed to treat solid tumors, and CM24 is in development as a combination therapy in non-small cell lung and pancreatic cancers.
Penny Stocks News You Can Use
Friday morning, shares of PPBT stock jumped early after its latest headline. The company announced a Phase 1b/2 clinical trial evaluating CM24 in advanced cancer patients, with expansion cohorts in non-small cell lung cancer and pancreatic cancer subjects. The trial includes clinical collaboration with Bristol Myers Squibb (NYSE: BMY). This is a dose-escalation study with treatments from 10mg/kg, targeting the 20mg/kg dose, combined with nivolumab in Phase 1b.
SenesTech Inc.
SenesTech is a bit of a different company in comparison to the others mentioned in this article. The company focuses on pest control. Animal tech companies have received decent attention recently. If you remember our articles on Zomedica, the company gained significant momentum as traders anticipated the company’s diagnostic device’s commercial launch.
[Read More] 3 Penny Stocks To Buy For Under $4 Right Now
In this case, SenesTech is more concerned about preventing population growth. Its technologies focus on fertility control in certain animal populations via its ContraPest system.
Penny Stocks News You Can Use
This week, the company announced the completion of a long-term agricultural deployment of ContraPest. SenesTech said that it demonstrated sustained success in reducing rat populations and improved operating economies in poultry settings. One of the egg farms that deployed ContraPest saw a 90% decrease in rat activity during the 12 months that it added the system.
Ken Siegel, CEO of SenesTech, commented, “While these results were from deployments at poultry facilities, the results are immediately applicable to many other agricultural situations. Anywhere there is high quality grain, there is the potential for rat infestations, and ContraPest is now proven in the field to reduce those infestations, reduce the negative economic impact, and improve overall food security.”
Check-Cap Ltd
Shares of Check-Cap Ltd. have been red-hot this year. CHEK stock kicked off the year at $0.72. Over the months to follow, it has reached highs of nearly $4.50. Plenty of the momentum was attributed to advancements in the development of its C-Scan device. This is the company’s product for scanning for colorectal cancer. It just got the green light from the FDA receiving an Investigational Device Exemption. This now allows Check-Cap to start a pivotal study of C-Scan in the U.S.
Penny Stocks News You Can Use
This week, there was a more fundamental catalyst helping to drive momentum in CHEK stock. The company reported its Q4 and full-year 2020 results. Among key highlights were its EPS growth. In 2020, Check-Cap reported a loss per share of 46 cents. This was significantly better than its 2019 loss per share of $1.73.
“We ended 2020 optimistically as we look forward to accomplishing our next significant milestone, the commencement of our U.S. pivotal study in late 2021,” said Alex Ovadia, Chief Executive Officer of Check-Cap. “The IDE approval granted by the FDA provides us with the opportunity to demonstrate the clinical efficacy of C-Scan in the U.S., and upon success, to potentially launch our product in the U.S. market.”
